Evaluation of [99mTc-(CO)3-X-Y-bombesin(744)NH 2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 19-30

  Retzloff, Lauren B ^a   Heinzke, Laura ^a   Figureoa, Said D ^a,c   Sublett, Samantha V ^c   Ma, Lixin ^a,c   Sieckman, Gary L ^c   Rold, Tammy L ^a,c   Santos, Isabel ^d   Hoffman, Timothy J ^a,b,c   Smith, Charles Jeffrey ^a,b,c  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE   (Portugal)

Author keywords

Breast cancer; Carbonyl; GRP receptor; MDA MB 231; T47 D; Technetium

Indexed keywords

2,3 DIAMINOPROPIONIC ACID; 99 M TC (CO)3 X Y BOMBESIN(7-14)NH 2; BOMBESIN DERIVATIVE; GASTRIN RELEASING PEPTIDE RECEPTOR; LIGAND; PYRAZOLE DERIVATIVE; TECHNETIUM 99M; UNCLASSIFIED DRUG; 2,3-DIAMINOPROPIONIC ACID; BETA ALANINE; BOMBESIN; DRUG DERIVATIVE; GASTRIN RELEASING PEPTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; BREAST CARCINOMA; CANCER TISSUE; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; METALLATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID PHASE SYNTHESIS; TARGET ORGAN; ANIMAL; BREAST TUMOR; DRUG DELIVERY SYSTEM; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE MUTANT; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BETA-ALANINE; BOMBESIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; GASTRIN-RELEASING PEPTIDE; HUMANS; MICE; MICE, INBRED ICR; MICE, SCID; ORGANOTECHNETIUM COMPOUNDS; PYRAZOLES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 77649250207     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American Cancer Society. Cancer Facts and Figures 2009 (on line). Available: http://www.cancer.org. Accessed September 20, 2009.
2. Parry JJ, Andrews R and Rogers BE: MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat 101: 175-183, 2007.
3. Lewin JM, D'Orsi CJ, Hendrick RE, Moss LJ, Isaacs PK, Karellas A and Cutter GR: Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. Am J Roent 179: 671-677, 2002.
4. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans III WP, Foster RS, Jr., Hendrick E, Eyre HJ and Sener S: American cancer society guidelines for breast cancer screening: update 2003. CA J Clin 53: 141-169, 2003.
5. Buchberger W, DeKoekkoek-Doll P, Springer P, Obrist P and Dunser M: Incidental findings on sonography of the breast: clinical significance and diagnostic workup. Am J Roent 173: 921-927, 1999.
6. Davis PL and McCarty KS, Jr.: Sensitivity of enhanced MRI for the detection of breast cancer: new, multicentric, residual, and recurrent. Eur Rad 7: S289-S298, 1997.
7. Freer TW and Ulissey MJ: Screening mammography with computer-aided detection: prospective study of 12,860 patients in a community breast center. Radiology 220: 781-786, 2001.
8. Kolb TM, Lichy J and Newhouse JN: Occult cancer in women with dense breasts: detection with screening US-diagnostic yield and tumor characteristics. Radiology 207: 191-199, 1998.
9. Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, Datsteris J and Archimandritis SC: Technetium-labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. CA Biotherapy Radiopharm 17: 327-335, 2002.
10. Van de Wiele C, Dumont F, Broecke RV, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Siegers G and Dierck RA: Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27: 1694-1699, 2000.
11. Blok D, Feitsma RIJ, Vermeij P and Pauwels EJK: Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 26: 1511-1519, 1999.
12. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN and Scopinaro F: Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28: 1555-1565, 2001.
13. Reubi JC, Mathias G and Waser B: Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med 29: 855-862, 2002.
14. Gugger M and Reubi JC: Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Path 155: 2067-2076, 1999.
15. Reubi JC, Gugger M, Waser B and Schaer JC: Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61: 4636-4641, 2001.
16. Halmos G, Wittliff JL and Schally AV: Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 55: 280-287, 1995.
17. 13, 14] Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Life Sci 37: 105-113, 1985.
18. Smith CJ, Volkert WA and Hoffman TJ: Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32: 733-740, 2005.
19. Smith CJ, Volkert WA and Hoffman TJ: Gastrin-releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Bio 30: 861-868, 2003.
20. Markwalder R and Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159, 1999.
21. 3-DTMA bombesin conjugates having high affinity for the GRP receptor. Nuc Med Bio 35: 263-272, 2008.
22. Marti N, Spingler B and Schibli R: Comparative studies of substitution reactions of rhenium(I) dicarbonyl-nitrosyl and tricarbonyl complexes in aqueous media. Inorg Chem 44: 6082-6091, 2005.
23. Schibli R and Schubinger PA: Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med 29: 1529-1542, 2002.
24. + cores. Inorganica Chim Acta 358: 3691-3700, 2005.
25. Hunter KW, Crawford NPS and Alsarraj J: Mechanisms of metastasis. Breast Cancer Res 10, 2008.
26. Koglin N and Beck-Sickinger AG: Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes. Neuropeptides 38: 153-161, 2004.
27. Giacchetti S, Gauville C, De Cremoux P, Bertin L, Berthon P, Abita JP, Cuttita F and Calvo F: Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer 46: 293-298, 1990.
28. Yano T, Pinski J, Groot K and Schally AV: Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52: 4545-4547, 1992.
29. Rogers BE, Curiel DT, Mayo MS, Laffoon KK, Bright SJ and Buchsbaum DJ: In vitro binding and internalization of an indium-111-labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. Nicolini M and Mazzi U (eds.). SGE Editoriali, Padova, Italy, pp. 519-525, 1999.
30. Engel JB, Schally AV, Halmos G, Baker B, Nagy A and Keller G: Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 12: 999-1009, 2005.
31. 188Re of peptide conjugates containing a dithia-bisphosphine chelating agent. Bioconjug Chem 12: 354-363, 2001.
32. Varvarigou A, Bouziotis P, Zikos C, Scopinaro F and De Vincentis G: Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm 19: 219-229, 2004.
33. 2: an in vitro/in vivo structure-activity relationship study where X=0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 14: 93-102, 2003.